Global Proliferative Vitreoretinopathy (PVR) Drug Pipeline Guide 2022 – ResearchAndMarkets.com

0

DUBLIN–(BUSINESS WIRE)–The “Proliferative Vitreoretinopathy (PVR) Drugs in Staged Development, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to from ResearchAndMarkets.com offer.

The pipeline guide provides an overview of the Proliferative Vitreoretinopathy (PVR) (Ophthalmology) pipeline landscape.

It provides comprehensive information on treatments in development for proliferative vitreoretinopathy, with analysis by stage of development, drug target, mechanism of action, route of administration and molecule type. The guide covers the therapeutic’s descriptive pharmacological action, its full research and development history, and the latest news and press releases.

The pipeline guide also reviews key players involved in proliferative vitreoretinopathy (PVR) therapeutic development and features dormant and discontinued projects. The guide covers therapies in Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery are respectively 1, 3 and 2. Similarly, the portfolio of universities in preclinical stages includes respectively 1 molecules .

The guide helps identify and track emerging players in the market and their portfolios, enhances decision-making capabilities, and helps create effective counter-strategies to gain competitive advantage. The guide is constructed using data and information from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, presentations investors and featured press releases from company/academic sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the latest developments are captured in real time.

Scope

  • The pipeline guide provides an overview of the global proliferative vitreoretinopathy (PVR) therapeutic landscape.

  • The pipeline guide reviews pipeline therapies for proliferative vitreoretinopathy (PVR) by companies and universities/research institutes based on information from company and industry specific sources.

  • The pipeline guide covers pipeline products based on multiple stages of development ranging from pre-registration to discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for pipeline products, which include a product description, descriptive licensing and collaboration details, R&D brief, MoA, and other development activities.

  • The pipeline guide reviews the major companies involved in proliferative vitreoretinopathy (PVR) therapeutics and lists all of their major and minor projects.

  • The pipeline guide evaluates therapeutics for proliferative vitreoretinopathy (PVR) based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.

  • The pipeline guide encapsulates all dormant and abandoned pipeline projects.

  • The pipeline guide reviews the latest news related to pipeline treatments for proliferative vitreoretinopathy (PVR)

Main topics covered:

Proliferative Vitreoretinopathy (PVR) – Overview

Proliferative Vitreoretinopathy (PVR) – Therapeutic Development

  • Pipeline Overview

  • Pipeline by companies

  • Pipeline by universities/institutes

  • Products under development by companies

  • Products under development by universities/institutes

Proliferative Vitreoretinopathy (VRP) – Therapeutic Assessment

  • Evaluation by target

  • Assessment by mechanism of action

  • Evaluation by route of administration

  • Evaluation by type of molecule

Proliferative Vitreoretinopathy (PVR) – Companies involved in therapeutic development

  • Aldeyra Therapeutics Inc

  • Aptitude Medical Systems Inc

  • Focal Point Pharmaceuticals Inc

  • Novartis AG

  • Panag Pharma Inc.

  • Ractigen Therapeutics Inc

Proliferative Vitreoretinopathy (PVR) – Drug Profiles

  • Aptamers for Inhibiting PDGF in Proliferative Vitreoretinopathy – Drug Profile

  • methotrexate – Pharmaceutical profile

  • OM-101 – Pharmaceutical profile

  • onternabez – Drug Profile

  • RAG-1C – Pharmaceutical profile

  • Small Molecules to Inhibit Hdm2 in Proliferative Vitreoretinopathy – Drug Profile

  • XOMA-089 – Drug Profile

Proliferative Vitreoretinopathy (PVR) – Dormant Projects

Proliferative Vitreoretinopathy (PVR) – Product Development Milestones

List of paintings

  • Number of products in development for proliferative vitreoretinopathy (PVR), 2022

  • Number of products under development by companies, 2022

  • Number of products under development by universities/institutes, 2022

  • Products under development by companies, 2022

  • Products under development by universities/institutes, 2022

  • Number of outputs by milestone and target, 2022

  • Number of products by stage and mechanism of action, 2022

  • Number of products by stage and route of administration, 2022

  • Number of products by stage and type of molecule, 2022

  • Proliferative Vitreoretinopathy (PVR) – Pipeline by Aldeyra Therapeutics Inc, 2022

  • Proliferative Vitreoretinopathy (PVR) – Pipeline by Aptitude Medical Systems Inc, 2022

  • Proliferative Vitreoretinopathy (PVR) – Pipeline by Focal Point Pharmaceuticals Inc, 2022

  • Proliferative Vitreoretinopathy (PVR) – Novartis AG Pipeline, 2022

  • Proliferative Vitreoretinopathy (PVR) – Pipeline by Panag Pharma Inc, 2022

  • Proliferative Vitreoretinopathy (PVR) – Pipeline by Ractigen Therapeutics Inc, 2022

Proliferative Vitreoretinopathy (PVR) – Dormant Projects, 2022

List of Figures

  • Number of products in development for proliferative vitreoretinopathy (PVR), 2022

  • Number of products under development by companies, 2022

  • Number of products by targets, 2022

  • Number of outputs by milestone and targets, 2022

  • Number of products by mechanism of action, 2022

  • Number of products by stage and mechanism of action, 2022

  • Number of products per route of administration, 2022

  • Number of products by stage and routes of administration, 2022

  • Number of products by type of molecule, 2022

  • Number of products by stage and types of molecules, 2022

Companies cited

  • Aldeyra Therapeutics Inc

  • Aptitude Medical Systems Inc

  • Focal Point Pharmaceuticals Inc

  • Novartis AG

  • Panag Pharma Inc.

  • Ractigen Therapeutics Inc

For more information on this report, visit https://www.researchandmarkets.com/r/4c4a50

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Share.

Comments are closed.